#1 Clinical Trials Search in Europe

Patiromer

Patiromer is an innovative drug being studied in clinical trials for the treatment of hyperkalemia, a condition characterized by high potassium levels in the blood. This article explores the use of patiromer in various clinical trials, focusing on its efficacy, safety, and potential benefits for patients with chronic kidney disease, heart failure, and other conditions associated with hyperkalemia.

Table of Contents

What is Patiromer?

Patiromer is a medication used to treat high levels of potassium in the blood, a condition known as hyperkalemia. It is also known by its brand name Veltassa and was previously referred to as RLY5016 during its development[1][2]. Patiromer is available as a powder that is mixed with water and taken orally (by mouth)[3].

What Conditions Does Patiromer Treat?

Patiromer is primarily used to treat hyperkalemia, which can occur in several conditions:

  • Chronic Kidney Disease (CKD): Patiromer is often used in patients with CKD who have high potassium levels[1].
  • Heart Failure: Patients with heart failure, especially those taking certain heart medications, may develop hyperkalemia and benefit from patiromer[4].
  • Diabetes: Particularly in patients with diabetic nephropathy (kidney disease caused by diabetes)[2].
  • Hypertension (High Blood Pressure): Some blood pressure medications can increase potassium levels, and patiromer may be used to manage this side effect[2].

How Does Patiromer Work?

Patiromer works by binding to excess potassium in your digestive tract. When you take patiromer orally, it travels through your digestive system and attaches to potassium. This bound potassium is then eliminated from your body through your stool, effectively lowering the amount of potassium in your blood[5].

Dosage and Administration

The dosage of patiromer can vary depending on your specific condition and potassium levels. Some common dosages include:

  • Starting doses ranging from 8.4 g/day to 25.2 g/day, taken once daily[2].
  • For children and adolescents, doses may be lower and are based on age and weight[1].
  • Your doctor may adjust your dose based on how your potassium levels respond to the treatment[2].

Patiromer is usually taken once daily, with or without food. However, it’s important to take it as directed by your healthcare provider[3].

Effectiveness of Patiromer

Clinical trials have shown that patiromer is effective in lowering potassium levels in patients with hyperkalemia. Some key findings include:

  • Patiromer can help maintain normal potassium levels in patients with chronic kidney disease and heart failure[6].
  • It allows patients to continue using important medications that may increase potassium levels, such as certain blood pressure medications or heart failure treatments[4].
  • The medication can be effective in both short-term and long-term management of hyperkalemia[2].

Potential Side Effects

Like all medications, patiromer can cause side effects. Common side effects may include:

  • Gastrointestinal symptoms such as constipation, diarrhea, or abdominal discomfort[7].
  • Low magnesium levels in the blood (hypomagnesemia)[2].

Your healthcare provider will monitor your blood levels regularly to check for any imbalances in electrolytes (such as potassium, magnesium, and calcium) while you’re taking patiromer[2].

Use in Special Populations

Patiromer has been studied in various patient groups:

  • Children and Adolescents: Research is ongoing to determine the safety and effectiveness of patiromer in patients aged 2 to 18 years[1].
  • Kidney Transplant Recipients: Studies have looked at how patiromer interacts with common transplant medications[8].
  • Dialysis Patients: Patiromer has been studied in patients undergoing hemodialysis[5].

Ongoing Research

Researchers continue to study patiromer to better understand its long-term effects and potential uses. Some areas of ongoing research include:

  • Use of patiromer in combination with other heart failure treatments to improve patient outcomes[4].
  • Effectiveness and safety of patiromer in children and adolescents with hyperkalemia[9].
  • Impact of patiromer on gut microbiome in patients with end-stage renal disease[7].

As with any medication, it’s important to discuss the potential benefits and risks of patiromer with your healthcare provider. They can provide personalized advice based on your specific health condition and needs.

Aspect Details
Primary Use Treatment of hyperkalemia in various patient populations
Patient Groups Chronic kidney disease, heart failure, diabetes, hemodialysis patients, kidney transplant recipients
Dosage Range 8.4 g/day to 33.6 g/day, with 8.4 g/day as a common starting dose
Administration Oral suspension, typically once or twice daily
Treatment Duration Varies from 4 weeks to 52 weeks or longer, depending on the study
Primary Outcomes Change in serum potassium levels, proportion of patients achieving normal potassium levels
Secondary Outcomes Safety profile, quality of life measures, cardiovascular events, mortality rates
Special Considerations Potential drug interactions, timing of administration relative to other medications
Age Groups Studied Adults, with some trials including children and adolescents
Ongoing Research Long-term safety, efficacy in specific patient populations, optimal dosing strategies

FAQ

  • What is patiromer and how does it work? Patiromer is a potassium-binding medication used to treat hyperkalemia (high potassium levels in the blood). It works by binding to excess potassium in the gut, preventing its absorption into the bloodstream and facilitating its removal from the body through feces.
  • Who can benefit from patiromer treatment? Patiromer may benefit patients with hyperkalemia, particularly those with chronic kidney disease, heart failure, or diabetes. It is also being studied in patients on hemodialysis and kidney transplant recipients who experience high potassium levels.
  • What are the typical doses of patiromer used in clinical trials? Clinical trials have explored various doses of patiromer, ranging from 8.4 g/day to 33.6 g/day. The starting dose is often 8.4 g/day, which can be adjusted based on individual patient response and potassium levels.
  • Are there any side effects associated with patiromer? While patiromer is generally well-tolerated, some patients may experience gastrointestinal symptoms. Clinical trials are monitoring for adverse events and assessing long-term safety. It's important to note that patiromer may affect the absorption of other medications, so proper timing of administration is crucial.
  • How long does patiromer treatment typically last? The duration of patiromer treatment varies depending on the study and patient needs. Some trials have investigated short-term use (4-8 weeks), while others have explored long-term treatment lasting up to 52 weeks or more to assess ongoing efficacy and safety.

Ongoing Clinical Trials on Patiromer

  • A study testing how well patiromer lowers high potassium levels in the blood in children under 12 years of age with hyperkalemia

    Recruiting

    1 1
    Investigated drugs:
    Belgium Finland France Greece Hungary Italy +5

  • Study of Patiromer to Allow Less Dietary Potassium Restrictions in Patients on Chronic Dialysis with Controlled Blood Potassium Levels

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Patiromer and Placebo for Managing Hyperkalemia in Non-Dialysis Patients with Chronic Kidney Disease Stages IIIB to V

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effect of Patiromer on Vascular Health in Patients with Chronic Kidney Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Hyperkalemia: A condition characterized by higher than normal levels of potassium in the blood, which can be dangerous and potentially life-threatening if left untreated.
  • Chronic Kidney Disease (CKD): A long-term condition where the kidneys do not function properly, often leading to complications such as hyperkalemia.
  • Hemodialysis: A medical procedure that filters waste products from the blood when the kidneys are not working properly, often used in patients with advanced kidney disease.
  • Mineralocorticoid Receptor Antagonist (MRA): A class of medications used to treat heart failure and high blood pressure, which can sometimes cause hyperkalemia as a side effect.
  • Serum Potassium: The level of potassium measured in the blood serum, used to diagnose and monitor hyperkalemia.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and physiological effects.
  • Titration: The process of adjusting the dose of a medication to achieve the desired therapeutic effect while minimizing side effects.
  • Adverse Events: Undesirable experiences associated with the use of a medical product, which may or may not be related to the treatment.
  • End-Stage Renal Disease (ESRD): The final stage of chronic kidney disease where the kidneys are no longer able to function adequately to sustain life without dialysis or transplantation.
  • Pharmacokinetics: The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.gov/study/NCT03087058
  2. https://clinicaltrials.gov/study/NCT01371747
  3. https://clinicaltrials.gov/study/NCT02694744
  4. https://clinicaltrials.gov/study/NCT04142788
  5. https://clinicaltrials.gov/study/NCT02033317
  6. https://clinicaltrials.gov/study/NCT01130597
  7. https://clinicaltrials.gov/study/NCT03326583
  8. https://clinicaltrials.gov/study/NCT03229265
  9. https://clinicaltrials.eu/trial/a-study-testing-how-well-patiromer-lowers-high-potassium-levels-in-the-blood-in-children-under-12-years-of-age-with-hyperkalemia/